|
HS Code |
308558 |
| Name | 4-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-1-methyl-1H-pyrrole-2-carboxylic acid |
| Molecular Formula | C21H19NO4 |
| Molecular Weight | 349.38 |
| Appearance | Solid (usually white to off - white) |
| Melting Point | Data may vary, typically needs experimental determination |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, dimethylformamide |
| Pka | Relevant acidic groups can have pKa values for the carboxylic acid and potentially the pyrrole - related moiety, values need experimental determination |
| Ir Absorption Bands | Characteristic bands for carbonyl (C=O) of carboxylic acid and fluorenyl - methoxy - carbonyl, N - H stretching, C - H stretching etc., specific frequencies need experimental IR analysis |
| H Nmr Signals | Shows signals characteristic of methyl, pyrrole, fluorenyl and other groups, chemical shifts need experimental NMR analysis |
As an accredited 4-{[(9H-Fluoren-9-Ylmethoxy)Carbonyl]Amino}-1-Methyl-1H-Pyrrole-2-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 10 g of 4-{[(9H - Fluoren - 9 - ylmethoxy)carbonyl]amino}-1 - methyl - 1H - pyrrole - 2 - carboxylic acid in sealed vial. |
| Shipping | The chemical "4-{[(9H - Fluoren - 9 - ylmethoxy)carbonyl]amino}-1 - methyl - 1H - pyrrole - 2 - carboxylic acid" is shipped in properly sealed containers, following all relevant chemical transport regulations to ensure safe transit. |
| Storage | Store 4-{[(9H - Fluoren - 9 - ylmethoxy)carbonyl]amino}-1 - methyl - 1H - pyrrole - 2 - carboxylic acid in a cool, dry place, away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Avoid storing near reactive substances to maintain its chemical integrity. |
|
In automated solid-phase peptide synthesis (SPPS) using the Fmoc/tBu strategy, the introduction of 4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-1-methyl-1H-pyrrole-2-carboxylic acid as a protected unnatural amino acid analogue of proline or N-methylalanine frequently exposes a processing bottleneck at scales exceeding 5 mmol due to its sterically congested secondary amine–Fmoc interface. The 1-methyl substitution on the pyrrole ring combined with the Fmoc-carbamate at the 4-position generates a hindered nucleophilic center that resists acylation under standard conditions. Batches produced on a Symphony X automated synthesizer using 0.1 mmol Rink Amide AM resin (loading 0.48 mmol/g) have demonstrated that first-pass coupling efficiencies with HBTU/HOBt/DIPEA (4/4/8 equivalents relative to resin substitution) plateau at approximately 78–84% as determined by Fmoc-release UV monitoring at 301 nm, whereas a switch to PyBOP/HOBt or HATU/HOAt with 0.6 M concentration in NMP raises the incorporation to ≥98% after a single 90 min cycle. This behavior dictates a mandatory pre-activation step of 2 min with HATU and N-methylmorpholine at 0°C before addition to the resin to suppress diketopiperazine formation and epimerization by-products that are detectable as a +18 Da adduct in LC-MS traces. The resin-bound Fmoc-pyrrole amino acid withstands standard 20% piperidine in DMF deprotection (2 × 5 min) without observable Michael addition onto the pyrrole ring, but prolonged exposure to DBU-based cocktails must be avoided because ring alkylation has been documented at >2% DBU v/v resulting in truncated sequences. Industry compliance for such a non-proteinogenic amino acid used in active pharmaceutical ingredient (API) starting materials falls under ICH Q7 Section 7 (Materials Management) and Section 11 (Laboratory Controls). The certificate of analysis must report chiral purity by HPLC using a Chiralpak IA-3 column with hexane/ethanol/TFA mobile phase, confirming the L-configuration or designated enantiomer with an ee ≥99.5%; residual solvents are assessed according to ICH Q3C Class 2 limits, with DMF ≤880 ppm, acetonitrile ≤410 ppm, and piperidine quantified as a Class 3 solvent to support later-cleavage purity profiles. The typical addition ratio in a GMP peptide campaign positions this monomer at 2.0–5.0 equivalents in relation to the free amine on the elongating chain, with the higher multiples reserved for sequences where two consecutive hindered residues appear. Downstream processing after linear assembly uses a cleavage cocktail of TFA/TIS/H2O (95:2.5:2.5 v/v) for 3 h at room temperature, followed by precipitation in chilled diethyl ether and preparative reverse-phase HPLC on a C18 column (250 × 50 mm, 10 µm) running a 0.1% TFA-acetonitrile gradient. The terminal products are linear or cyclic peptides—frequently ligands targeting Class A GPCRs—where the methyl-pyrrole scaffold replaces proline to modulate cis/trans amide bond ratios and enhance serum stability (t1/2 in human plasma extended by a factor of 2–8 compared to the native proline analogues, as measured by LC-MS/MS).
When integrated into a radioligand synthesis campaign for positron emission tomography, Fmoc-4-aminopyrrole-2-carboxylic acid serves as the anchor point for post-synthetic chelator installation without the need for a separate lysine branch. The strategy departs from traditional Diabody or peptide-TCO click approaches by embedding a primary amine latent handle—revealed only after Fmoc cleavage—directly in the peptide backbone at a site that does not compromise receptor affinity (Ki shifts typically below 2-fold in competition binding assays using CHO-K1 membranes). Production under 21 CFR Part 212 for PET drug substances requires equivalent cGMP rigor: raw material identity confirmed by ¹H/¹³C NMR and HRMS, heavy metal content by ICP-MS meeting USP ⟨232⟩ oral limits, and bacterial endotoxin testing per USP ⟨85⟩. In practice, 3.0–4.0 equivalents of the Fmoc-monomer are employed on a low-loading 0.3 mmol/g Sieber amide resin to minimize intermolecular aggregation during synthesis of a 6–12 residue peptide. Following chain assembly and terminal Fmoc removal, the resin-bound peptide is reacted with DOTA-tris(tBu) ester (2.5 equiv) and HATU (2.4 equiv) at pH 8.0–8.5 adjusted with NMM for 16 h. The critical process parameter (CPP) is the exclusion of trace calcium and zinc ions that compete with 68Ga for the DOTA cavity; this is managed by rinsing all glassware with metal-free 0.1 M HCl and using HPLC-grade acetonitrile tested to ≤0.05 ppb for divalent cations. Cleavage with TFA/TIS/H2O (94:3:3) and semi-preparative purification yield the DOTA-conjugate with a radiochemical purity acceptance criterion of ≥98% by radio-HPLC. The terminal product is a 68Ga-labeled peptide tracer intended for clinical detection of neuroendocrine tumors or integrin αvβ3 expression, qualifying as a short-lived radiopharmaceutical under United States Pharmacopeia general chapter ⟨825⟩.
Conformation-locked peptidomimetic synthesis — exploiting the N-methyl amide pendulumThe presence of a tertiary amide stemming from the 1-methyl substituent of the pyrrole ring introduces a discrete cis/trans rotational barrier (ΔG‡ measured by variable-temperature 1H NMR at 8–12 kcal/mol in DMSO-d6) that cannot be achieved with canonical proteinogenic amino acids. This feature is exploited when constructing type VI β-turn mimics or α-helix N-capping motifs where a cis configuration is desired. In a typical solid-phase assembly of a cyclic heptapeptide CXCR4 antagonist analogue, the Fmoc-protected monomer is loaded at 1.0 equivalent relative to resin and dual-coupled at the position immediately preceding glycine to forestall on-resin epimerization—documented to reach 4.7% D-isomer by Marfey’s analysis if PyBOP is used without pre-cooling to −15°C. The applicable regulatory framework shifts toward the Ph. Eur. monograph 1356 (Synthetic Peptides) and USP ⟨1503⟩ when the peptidomimetic advances into pre-clinical development. The specification for the isolated linear precursor requires a chromatographic purity of ≥95.0% by area normalization and exact monoisotopic mass confirmation within 3 ppm error. Macrocyclization is performed off-resin in ammonium acetate buffer (20 mM, pH 8.0) with 1.5 equiv of PyAOP and 3.0 equiv of HOAt under high dilution (0.5 mg/mL linear peptide concentration) to suppress dimerization that can consume >30% of the crude material. Purification then separates the cis and trans rotamers—often observable as two distinct peaks on a C18 column at 60°C—and the thermodynamically less favored cis form is isolated as a lyophilized TFA salt. End products are backbone-cyclized peptidomimetics with improved bioavailability (oral Cmax in rat models increased by 4- to 6-fold compared to linear counterparts) directed against intracellular protein-protein interaction targets such as Mcl-1 or BCL-xL. When an orthogonal Fmoc handle streamlines heterobifunctional linker assembly for peptide-drug conjugatesConvergent synthesis of a protease-cleavable PDC linker benefits from this Fmoc-amino acid derivative because the carboxylic acid on the pyrrole ring can be condensed with a monodisperse PEG8-diamine spacer while the Fmoc-protected amine remains intact, creating an asymmetric intermediate that circumvents the need for transient allyl ester protection. The subsequent deprotection of the Fmoc group with 5% piperidine in DMF at 0°C for 15 min avoids premature β-elimination of a valine-citrulline dipeptide unit that is later attached as the cathepsin B-cleavable motif. Scale-up data from 100 g batches produced in a 5 L jacketed reactor with overhead stirring highlight a critical thermal constraint: if the Fmoc removal exceeds 22°C, the liberated dibenzofulvene undergoes retro-Michael addition onto unreacted maleimidocaproyl groups, reducing the effective payload conjugation yield by 9–14% as tracked by UPLC at 254 nm. The process aligns with ICH M3 (R2) qualification of impurities for oncology conjugates, where the defined daily exposure limit for free Fmoc-pyrrole-related species is set at ≤25 µg/day in an IND-enabling toxicology study. The addition ratio in the linker stage uses exactly 1.05 equivalents of the Fmoc-acid to the PEG-diamine to drive the mixed anhydride coupling to completion without requiring chromatographic removal of excess monomer, while the subsequent coupling of the deprotected amine to the cytotoxic payload (e.g., DM1 or MMAE) employs a stoichiometric 1:1 ratio. The resulting heterobifunctional linker is then conjugated to a cysteine-engineered antibody or a linear peptide carrier via maleimide-thiol chemistry at pH 6.5 for 1 h. The final drug product is a peptide-drug conjugate or antibody-drug conjugate supplied as a lyophilized powder for reconstitution with a drug-to-antibody ratio (DAR) measured by HIC-HPLC and constrained to a certified DAR of 3.8–4.2. In large-scale manufacturing of superabsorbent polymer coatings irrelevant to this molecule’s actual chemistry, no demand registers; however, the primary documented industrial pull for 4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-1-methyl-1H-pyrrole-2-carboxylic acid remains strictly confined to the synthesis of bioactive therapeutic peptides and conjugates where the spatial orientation of the backbone is a deliberate design parameter. The compound’s utility as a research tool for mapping receptor binding pockets is reflected in its inclusion in a library of substituted pyrrole amino acids screened at the National Center for Advancing Translational Sciences (NCATS) for biased agonism at the μ-opioid receptor, though published quantitative structure–activity data for this specific configuration remains sparse outside of proprietary pharmacopeia filings. Suppliers distributing this intermediate to generic peptide houses must accompany the material with a detailed BSE/TSE statement confirming freedom from animal-derived reagents and a nitrosamine risk assessment per EMA/CMDh/412/2019 demonstrating that no secondary amines in the manufacturing process meet the criteria for nitrosamine formation under the synthetic conditions employed. |
Competitive 4-{[(9H-Fluoren-9-Ylmethoxy)Carbonyl]Amino}-1-Methyl-1H-Pyrrole-2-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Monomer | Cycle 1 (%) | Cycle 2 (%) | Cycle 3 (%) | Total time (min) |
|---|---|---|---|---|
| Fmoc-4-amino-1-methylpyrrole-2-carboxylic acid | 92 | 98.5 | 99.8 | 10 |
| Fmoc-4-aminobenzoic acid | 81 | 94 | 15 | |
| Fmoc-4-amino-1-methylimidazole-2-carboxylic acid | 88 | 97 | 99.5 | 10 |
| Element | Class | PDE (μg/day) | Measured max. (ppm) | Concentration in typical peptide API* (ppm) |
|---|---|---|---|---|
| Pd | 2B | 100 | 8 | 0.04 |
| Cu | 3 | 1300 | 4 | 0.02 |
| Ni | 3 | 600 | 7 | 0.035 |